Startup closes series A, Houston hospital taps into new tech, and more local innovation news

short stories

The Texas Medical Center is buzzing with recent innovation news, from Texas A&M University naming its buildings, Houston Methodist is introducing a new technology, and more. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks.

For this roundup of short stories within Houston innovation, Deloitte is looking for tech companies to honor, a few Houston innovators have fresh funds, buildings rising in the Texas Medical Center now have names, and more.

Texas A&M names buildings in Innovation Plaza

Texas A&M University has named the buildings that will be a part of its Innovation Plaza. Photo courtesy of Texas A&M University System

The Texas A&M University System has revealed the names of the three buildings in the Texas A&M Innovation Plaza rising near the Texas Medical Center: Discovery Tower, Life Tower, and Horizon Tower.

Discovery Tower is the future home of A&M's EnMed program and is currently being renovated from an 18-story office building. Life Tower, which is expected to deliver in June 2022, is a 19-story, 714-bed student housing tower for Texas A&M medical students and Prairie View A&M University nursing students. Lastly, the Horizon Tower will be a 17-story, 485,000 square-foot integrated building that will feature a 13-story parking structure at the bottom.

SecurityGate closes series A

Ted Gutierrez, CEO of SecurityGate, announced the closing of his company's series A. Courtesy of Security Gate

SecurityGate.io, a software-as-a-service cybersecurity startup based in Houston, has closed its series A fundraising round. Houston Ventures led the capital raise. The amount raised has not been disclosed.

"It was very attractive to us how tightly tuned SecurityGate.io is to the needs of their customers," says Chip Davis, managing partner at Houston Ventures, in a news release. "Successful enterprise software companies generally know they are instruments of change for their customers."

Davis says the feedback from SecurityGate's customers was what sealed the deal.

"Digital transformation is no easy task in highly dynamic environments, especially when the risk of cyberattacks keeps rising daily. We're excited to partner with Houston Ventures who sees this market growing, and our clients that see our vision of the future," says Ted Gutierrez, CEO of SecurityGate, in the release.

Well Health launches at Houston Methodist

Thanks to tech from the West Coast, a Houston hospital has optimized virtual visits. Courtesy of Methodist Hospital/Facebook

Through a partnership with California-based WELL Health Houston Methodist was able up the ante on virtual visits during the pandemic. According to a news release, WELL enabled Houston Methodist to deliver over 260,000 text messages to patients Houston Methodist. The messages educated them about virtual care, schedule visits, and more.

"The ability to communicate back and forth, assuring patients that we are here for them both virtually and in-person is crucial as we continue to safely provide care in the midst of this pandemic," says Tesha Montgomery, vice president of operations and patient access at Houston Methodist, in the release.

Houston podcast network raises over $1 million

A podcast network with Houston ties has raised a seed round. Pexels

Lemonada Media, a podcast network with Houston roots that launched in September, has raised $1.38 million in a seed funding round led by Blue Collective, an early-stage venture capital firm. The fresh funds will allow for strategic growth for the two co-founders, Jessica Cordova Kramer, CEO, and Houstonian Stephanie Wittels Wachs, chief creative officer. Lemonada also plans to hire several positions including vice presidents across finance, production, and marketing.

"We are slated to be a content and talent incubator, spinning out new audio concepts and hit series that present humanity, unfiltered," says Wittels Wachs in a news release. "Now more than ever, people are hungry for content that addresses their lived experience, those that are mundane, and those that may be painful and isolating. Because our company was built off a mountain of personal grief and loss, Lemonada is well-situated to cut through the noise, create beautiful works of art, and make people laugh and feel less alone along the way."

Deloitte is looking for tech companies for annual competition

For the 26th year, Deloitte is looking for cutting edge tech companies. Photo courtesy of Deloitte

Deloitte has opened applications for its 2020 Technology Fast 500. The application is available online and closes July 17. To be eligible for the award, the startup must be in business for a minimum of four years, have its headquarters in North America, have fiscal year 2016 operating revenues of at least $50,000, a fiscal year 2019 operating revenues of at least $5 million USD with a growth rate of 75 percent or greater, and own proprietary intellectual property or proprietary technology which must be sold to customers in products or services that contribute to a majority of the company's operating revenues, according to the contest's rules.

Companies should also fall within one of the following industry categories: biotechnology/pharmaceutical, communications/networking, digital content/media/entertainment, electronic devices/hardware, energy tech, medical devices, semiconductor, or software/SaaS.

Lazarus 3D delivers PPE to Haiti

A few Houston innovators have helped get Haitians critical PPE. Photo courtesy of Orolait

A few Houston innovators have helped connect health care workers in Haiti to some PPE. Ana Rojas Bastidas, founder of Orolait, and Jacques and Smriti Agrawal Zaneveld of Lazarus 3D, teamed up to ship over 1,000 pieces of PPE to United States Foundation for the Children of Haiti which supported orphanages, schools, and a hospital called Hopital Espoir.

In the middle of April, Bastidas saw the organization's need for PPE and saw how Lazarus 3D was creating materials. The group in Haiti received the supplies by the beginning of June.

"I'm really proud of the collaboration between myself and the Lazarus 3D team," Bastidas says. "Smriti and Jacques are absolute gems and while our businesses are completely separate, we found a common problem we both had the resources to tackle."

CryptoEQ begins offering consulting packages

Need custom cryptocurrency support? CryptoEQ is here to help. Courtesy of CryptoEQ

A cryptocurrency startup based in Houston has expanded its service to include custom-consulting packages.

"With our personalized packages, gain the market insights you need to refine your cryptocurrency investing and trading strategies," writes Spencer Randall, co-founder and principal of CryptoEQ.

The packages come at three levels: the enthusiast, the professional, and the expert. The individualized support begins at $499, and more information can be requested from the startup by emailing team@cryptoeq.io.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings